Drugs / HSCT using a graft enriched in CD34+ hematopoietic progenitor cells
HSCT using a graft enriched in CD34+ hematopoietic progenitor cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06997471 | Jun 2025 → Jun 2028 expected | disease related to solid organ transplantation, transplant rejection | Francisco Hernández Oliveros | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSCT using a graft enriched in CD34+ hematopoietic progenitor cells | “HSCT using a graft enriched in CD34+ hematopoietic progenitor cells” NCT06997471 ↗ |
| Modality | Cell therapy | “Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+” NCT06997471 ↗ |
| Route | Intravenous | “will be intravenously infused” NCT06997471 ↗ |